ADAR1 Capital Management’s IO Biotech IOBT Stock Holding History

ADAR1 Capital Management’s Portfolio IOBT Stock Details IOBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,964	Closed	-$15.2K	–	326
2025 Q4	$15.2K	Buy	+24,964	New	+$18.6K	﹤0.01%	269

Other funds holding IOBT

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return

ADAR1 Capital Management's IOBT Position: Q1 2026 in Review

ADAR1 Capital Management sold out of IO Biotech (IOBT) in Q1 2026, closing a stake of 24,964 shares — an estimated $15.2K sold.

ADAR1 Capital Management first reported a position in IOBT in Q4 2025 and held it in 1 quarter. The position peaked at $15.2K in Q4 2025. 12 funds tracked by Wall St. Rank hold IOBT as of Q1 2026.

ADAR1 Capital Management reported no remaining IO Biotech position as of Q1 2026 after selling out during the quarter.
ADAR1 Capital Management sold 24,964 IO Biotech shares in Q1 2026, an estimated $15.2K.
ADAR1 Capital Management first reported a position in IO Biotech in Q4 2025 and held it in 1 quarter.
ADAR1 Capital Management's IO Biotech position peaked at $15.2K in Q4 2025.
12 funds tracked by Wall St. Rank held IO Biotech as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.